Hitting more birds with one stone: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma
M. Seyfrid, W. Maich, V. M. Shaikh, N. Tatari, D. Upreti, D. Piyasena, M. Subapanditha, N. Savage, D. McKenna, L. Kuhlmann, A. Khoo, S. K. Salim, B. Bassey-Archibong, W. D. Gwynne, C. Chokshi, , S. K. Singh
This study identifies CD70 as a therapeutic target for recurrent glioblastoma, showing that CD70 knockdown reduces tumorigenicity and CD70 CAR-T therapy improves survival in animal models.
bioRxiv · Jun 2, 2021 · PreprintCancer Biology